Belagenpumatucel-L for the treatment of non-small cell lung cancer

Bibliography

• Rijavec E, Genova C, Alama A, et al. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer. Future Oncol 2014;10(1):79-90
   PubMed Web of Science ®Google Scholar
• Rijavec E, Genova C, Barletta G, et al. Ipilimumab in non-small cell lung cancer and small-cell lung cancer: new knowledge on a new therapeutic strategy. Expert Opin Biol Ther 2014;14(7):1007-17
   PubMed Web of Science ®Google Scholar
• Sundar R, Cho BC, Brahmer JR, Soo RA. Nivolumab in NSCLC: latest evidence and clinical evidential. Ther Adv Med Oncol 2015;7(2):85-96
   PubMed Web of Science ®Google Scholar
• Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480(7378):480-9
   PubMed Web of Science ®Google Scholar
• Espinoza-Delgado I. Cancer Vaccines. Oncologist 2002;7(3):20-33
   PubMed Web of Science ®Google Scholar
• Srivatsan S, Patel JM, Bozeman E, et al. Allogeneic tumor cell vaccines. The promise and limitations in clinical trials. Hum Vaccin Immunother 2014;10(1):52-63
   PubMed Web of Science ®Google Scholar
• Hrouda D, Todryk SM, Perry MJA, et al. Allogeneic whole-tumour cell vaccination in the rat model of prostate cancer. BJU Int 2000;86:742-8
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010;363(5):411-22
   PubMed Web of Science ®Google Scholar
• Nemunaitis J, Dillman RO, Schwarzenberger PO, et al. Phase II study of Belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J Clin Oncol 2006;24:4721-30
   PubMed Web of Science ®Google Scholar
• Tyagi P, Mirakhur B. MAGRIT: the largest-ever phase III lung cancer trial aims to establish a novel tumor-specific approach to therapy. Clin Lung Cancer 2009;10(5):371-4
   PubMed Web of Science ®Google Scholar
• Vansteenkiste JF, Cho B, Vanakesa T, et al. MAGRIT, a double-blind, randomized, placebo-controlled phase III study to assess the efficacy of the RECMAGE-A3 AS15 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3 positive non-small cell lung cancer (NSCLC). Ann Oncol 2014;25:abstract 11730
   Web of Science ®Google Scholar
• Bafna S, Kaur S, Batra SK. Membrane-bound mucins: the mechanistic basis for alterations in the growth and survival of cancer cells. Oncogene 2010;29:2893-904
   PubMed Web of Science ®Google Scholar
• Butts C, Murray N, Maksymiuk A, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005;23:6674-81
   PubMed Web of Science ®Google Scholar
• Guan HH, Budzynski W, Koganty R, et al. Liposomal formulations of synthetic MUC1 peptides: Effects of encapsulation versus surface display of peptides on immune responses. Bioconjug Chem 1998;9:451-8
   PubMed Web of Science ®Google Scholar
• Butts C, Socinski MA, Mitchell PL, et al. Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial. Lancet Oncol 2014;15:59-68
   PubMed Web of Science ®Google Scholar
• Mitchell PL, Thatcher N, Socinski MA, et al. Tecemotide in unresectable stage III non-small cell lung cancer in the phase III START study: Updated overall survival and biomarker analyses. Ann Oncol 2015. [Epub ahead of print]
   Web of Science ®Google Scholar
• Limacher JM, Quoix E. TG4010: A therapeutic vaccine against MUC1 expressing tumors. Oncoimmunology 2012;1(5):791-2
   PubMed Web of Science ®Google Scholar
• Quoix E, Ramlau R, Westeel V, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer : a controlled phase 2B trial. Lancet Oncol 2011;12(12):1125-33
   PubMed Web of Science ®Google Scholar
• NCT01383148. Phase IIB/III of TG4010 immunotherapy in patients with stage IV non-small cell lung cancer (TIME). Available from: https://clinicaltrials.gov/ct2/show/NCT01383148?term=TG4010+and+nsclc&rank=1
   Google Scholar
• Vazquez AM, Hernandez AM, Macias A, et al. Racotumomab: an antiidiotype vaccine related to N-glycolyl-containing gangliosides – preclinical and clinical data. Front Oncol 2012;2:150
   Google Scholar
• Diaz Y, Gonzalez A, Lopez A, et al. Anti-ganglioside anti-idiotypic monoclonal antibody-based cancer vaccine induces apoptosis and antiangiogenic effect in a metastatic lung carcinoma. Cancer Immunol Immunother 2009;58(7):1117-28
   PubMed Web of Science ®Google Scholar
• Alfonso S, Valdés-Zayas A, Santiesteban ER, et al. A randomized, multicenter, placebo-controlled clinical trial of racotumomab-alum vaccine as switch maintenance therapy in advanced non-small cell lung cancer patients. Clin Cancer Res 2014;20(14):3660-71
   PubMed Web of Science ®Google Scholar
• NCT01460472. Immunotherapy with racotumomab in advanced lung cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01460472?term=racotumomab+and+nsclc&rank=1
   Google Scholar
• Neninger Vinageras E, de la Torre A, Osorio Rodriguez M, et al. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced NSCLC. J Clin Oncol 2008;26(9):1452-8
   PubMed Web of Science ®Google Scholar
• NCT01444118. Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, late stage (IIIb/IV) NSCLC patients eligible to receive standard treatment and supportive care. Available from: https://clinicaltrials.gov/ct2/show/NCT01444118?term=EGF+VACCINE+AND+NSCLC&rank=1
   Google Scholar
• Herrera ZM, Ramos TC. Pilot study of a novel combination of two therapeutic vaccines in advanced non-small-cell lung cencer patients. Cancer Immunol Immunother 2014;63(7):737-47
   PubMed Web of Science ®Google Scholar
• Javelaud D, Mauviel A. Mammalian transforming growth factor- βs: smad signaling and physio-pathological roles. Int J Biochem Cell Biol 2004;36(7):1161-5
   PubMed Web of Science ®Google Scholar
• Attisano L, Carcamo J, Ventura F, et al. Identification of human activin and TGF β type I receptors that form heteromeric kinase complexes with type II receptors. Cell 1993;75:1-10
   PubMed Web of Science ®Google Scholar
• Pick E, Heldin CH, Dijke PT. Specificity, diversity, and regulation in TGF-β superfamily signaling. FASEB J 1999;13:2105-24
   PubMed Web of Science ®Google Scholar
• Siegel PM, Massaguè J. Cytostatic and apoptotic actions of TGF-βeta in homeostasis and cancer. Nat Rev Cancer 2003;3:807-21
   PubMed Web of Science ®Google Scholar
• Valcourt U, Kowanetz M, Niimi H, et al. A TGFβ and the Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transition. Mol Biol Cell 2005;16:1987-2002
   PubMed Web of Science ®Google Scholar
• Thomas DA, Massaguè J. TGF-β directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-80
   PubMed Web of Science ®Google Scholar
• Zhang H, Yang P, Zhou H, et al. Involvement of Foxp3-expressing CD4+CD25+ regulatory T cells in the development of tolerance induced by transforming growth factor-β2-treated antigen-presenting cells. Immunology 2008;124(3):304-14
   PubMed Web of Science ®Google Scholar
• Saito H, Tsujitani S, Oka S, et al. An elevated serum level of trasforming growth factor-beta 1 (TGF-beta 1) significantly correlated with lymph node and metastasis and poor prognosis in patients with gastric carcinoma. Anticancer Res 2000;20(6b):4489-93
   PubMed Web of Science ®Google Scholar
• Papadopoulou E, Anagnostopoulos K, Tripsianis G, et al. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma 2008;55(3):229-38
   PubMed Web of Science ®Google Scholar
• Huang AL, Liu SG, Qi WJ, et al. TGF-β1 protein expression in non-small cell lung cancers is correlated with prognosis. Asian Pac J Cancer Prev 2014;15(19):8143-7
   PubMed Web of Science ®Google Scholar
• Fakhrai H, Tong A, Nemunaitis J, Shawler DL. Correlation of immune responses and survival in a phase II study of belagenpumatucel-L in non-small cell lung cancer. J Clin Oncol 2009;27:Abstract 3013
   Google Scholar
• Nemunaitis J, Nemunaitis M, Senzer N, et al. Phase II trial of belagenpumatucel-L, a TGF-β2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients. Cancer Gene Ther 2009;16:620-4
   PubMed Web of Science ®Google Scholar
• Giaccone G, Bazhenova L, Nemunaitis J, et al. A phase III study of belagenpumatucel-L therapeutic tumor cell vaccine for non-small-cell lung cancer (NSCLC). Eur J Cancer 2013;47(2):Abstract 7081
   Google Scholar
• Bazhenova L, Giaccone G, Nemunaitis JJ, et al. An International, multicenter, randomized, double-blind phase III study of maintenance belagenpumatucel-l in non-small cell lung cancer (NSCLC): updated analysis of patients enrolled within 12 weeks of completion of chemotherapy. J Clin Oncol 2014;32:abstract 8056
   Google Scholar
• Tagliamonte M, Petrizzo A, Tornesello ML, et al. Antigen-specific vaccines for cancer treatment. Hum Vaccin Immunother 2014;10(11):3332-46
   PubMed Web of Science ®Google Scholar
• Domagala-Kulawik J. The role of the immune system in non-small cell lung carcinoma and potential for therapeutic intervention. Transl Lung Cancer Res 2015;4(2):177-90
   PubMedGoogle Scholar
• Woo EY, Yeh H, Chu CH, et al. Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002;168:4272-6
   PubMed Web of Science ®Google Scholar
• Hodge JW, Ardiani A, Farsaci B, et al. The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors. Semin Oncol 2012;39(3):323-39
   PubMed Web of Science ®Google Scholar
• Morse MA, Osada T, Hobeika A, et al. Biomarkers and correlative endpoints for immunotherapy trials: what can we learn in lung cancer from other tumor types? Am Soc Clin Oncol Educ Book 2013;10.1200/EdBook_AM.2013.33.e287
   Google Scholar
• Almufti R, Wilbaux M, Oza A, et al. A critical review of the analytical approaches for circulating tumor biomarker kinetics during treatment. Ann Oncol 2014;25(1):41-56
   PubMed Web of Science ®Google Scholar
• Truini A, Alama A, Dal Bello MG, et al. Clinical applications of circulating tumoral cells in lung cancer patients by CellSearch system. Front Oncol 2014;4:242-6
   Google Scholar
• Ulloa-Montoya F, Louahed J, Dizier B, et al. Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy. J Clin Oncol 2013;31:2388-95
   PubMed Web of Science ®Google Scholar
• Fenoglio D, Parodi A, Lavieri L, et al. Immunogenicity of GX301 cancer vaccine: Four (telomerase peptides) are better than one. Hum Vaccin Immunother 2015;11(4):838-50
   PubMed Web of Science ®Google Scholar